Dr. Brad Rovin, director of the Division of Nephrology and the Vice Chair of Research in Internal Medicine at the Ohio State University, discusses IgA nephrology. Dr. Rovin is deputy editor of Kidney International and the co-chair of glomerular disease guidelines for KDIGO. He has published many major landmark nephrology clinical trials, including the BLISS and AURORA trials in lupus nephritis and the NefIgArd targeted-release budesonide trial in IgA nephropathy, which he highlights in this podcast.

Links to mentioned publications in this episode: 

BLISS https://www.nejm.org/doi/10.1056/NEJMoa2001180?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

AURORA https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00578-X/fulltext 

TESTING https://jamanetwork.com/journals/jama/fullarticle/2792252   NefIgArd https://www.kidney-international.org/article/S0085-2538(22)00836-5/fulltext  

Meta-analysis SGLT2 inhibitors https://www.thelancet.com/action/showPdf?pii=S0140-6736%2822%2902074-8